Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis

Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases

(2021) Preeti Kanikarla Marie et al.   CLINICAL CANCER RESEARCH

Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions

(2020) Malek Kreidieh et al.   Biomed Research International

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer

(2020) Eric X. Chen et al.   JAMA Oncology

Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy

(2020) Marc T Roth et al.   Expert Review of Anticancer Therapy

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy in colorectal cancer: rationale, challenges and potential

(2019) Karuna Ganesh et al.   Nature Reviews Gastroenterology & Hepatology

PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy

(2019) Arash Salmaninejad et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer

(2019) Jiajing Cai et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).

(2019) Joleen Marie Hubbard et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety of Nivolumab plus Low‐Dose Ipilimumab in Previously Treated Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer

(2019) Michael A. Morse et al.   ONCOLOGIST

Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies

(2019) NaNa Keum et al.   Nature Reviews Gastroenterology & Hepatology

Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy

(2019) Michael A. Morse et al.   ONCOLOGIST

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

(2019) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Colorectal cancer

(2019) Evelien Dekker et al.   LANCET

Promising New Agents for Colorectal Cancer

(2018) Satya Das et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Results and challenges of immune checkpoint inhibitors in colorectal cancer

(2018) Sheik Emambux et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Nivolumab for the treatment of colorectal cancer

(2018) Kortnye Maureen Smith et al.   Expert Review of Anticancer Therapy

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Clinical outcome of patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with pembrolizumab.

(2018) Frank A. Sinicrope et al.   JOURNAL OF CLINICAL ONCOLOGY

Current status of immunotherapy in metastatic colorectal cancer

(2018) Pawel Wrobel et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer

(2018) Neda Yaghoubi et al.   BIOMEDICINE & PHARMACOTHERAPY

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

(2017) Van K Morris et al.   LANCET ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

(2017) Bert H. O’Neil et al.   PLoS One

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Obesity and colorectal cancer: molecular features of adipose tissue

(2016) Javier Martinez-Useros et al.   Journal of Translational Medicine

Immunotherapy of melanoma: Present options and future promises

(2015) Anand Rotte et al.   CANCER AND METASTASIS REVIEWS

PD-1/PD-L1 inhibitors

(2015) Joel Sunshine et al.   CURRENT OPINION IN PHARMACOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy

(2015) Yanping Xiao et al.   Cancer Discovery

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer

(2010) Ki Y. Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

(2010) David Moher et al.   International Journal of Surgery

Treatment in advanced colorectal cancer: what, when and how?

(2009) I Chau et al.   BRITISH JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis

(2008) William M. Grady et al.   GASTROENTEROLOGY